A Randomized Trial Of Low-Dose Bevacizumab Versus Laser For Type 1 Retinopathy Of Prematurity

Grants and Contracts Details


ABSTRACT A RANDOMIZED TRIAL OF LOW-DOSE BEVACIZUMAB VERSUS LASER FOR TYPE 1 RETINOPATHY OF PREMATURITY This randomized clinical trial will compare retinal outcomes with low-dose intravitreous bevacizumab (0.063 mg) versus laser photocoagulation as treatment for infants with type 1 retinopathy of prematurity (ROP). The study also will assess neurodevelopment, refractive error, visual acuity, and peripheral visual fields. The primary objective is to determine if infants with type 1 ROP treated with intravitreous bevacizumab have retinal treatment success rates that are noninferior to that of infants treated with laser photocoagulation. Secondary objectives are to compare the number of re-treatments, extent of retinal vascularization, refractive error, visual acuity, visual fields, neurodevelopment, and systemic morbidities between treatment groups
Effective start/end date11/1/217/19/24


  • Jaeb Center for Health Research Foundation Incorporated: $7,573.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.